For example, treatment of AML patients with cytarabine and idarubicin has been shown to increase BCL-2 expression in the CD34+ compartment46 and high de novo expression of BCL-2 is correlated with poor response to treatment90,91, indicating scope for venetoclax combinations in AML. The gene discussed is BCL2; the disease is acute myeloid leukemia.